↓ Skip to main content

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis

Overview of attention for article published in Journal of Cancer Research & Clinical Oncology, March 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
18 Mendeley
Title
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis
Published in
Journal of Cancer Research & Clinical Oncology, March 2017
DOI 10.1007/s00432-017-2402-x
Pubmed ID
Authors

Francis J. Giles, Delphine Rea, Gianantonio Rosti, Nicholas C. P. Cross, Juan Luis Steegmann, Laimonas Griskevicius, Philipp le Coutre, Daniel Coriu, Ljubomir Petrov, Gert J. Ossenkoppele, Francois-Xavier Mahon, Susanne Saussele, Andrzej Hellmann, Perttu Koskenvesa, Tim H. Brümmendorf, Gunther Gastl, Fausto Castagnetti, Beatrice Vincenzi, Jens Haenig, Andreas Hochhaus

Abstract

Achievement of deep molecular response with a tyrosine kinase inhibitor in patients with chronic myeloid leukemia (CML) is required to attempt discontinuation of therapy in these patients. The current subanalysis from the Evaluating Nilotinib Efficacy and Safety in Clinical Trials as First-Line Treatment (ENEST1st) study evaluated whether age has an impact on the achievement of deeper molecular responses or safety with frontline nilotinib in patients with CML. ENEST1st is an open-label, multicenter, single-arm, prospective study of nilotinib 300 mg twice daily in patients with newly diagnosed CML in chronic phase. The patients were stratified into the following 4 groups based on age: young (18-39 years), middle age (40-59 years), elderly (60-74 years), and old (≥75 years). The primary end point was the rate of molecular response 4 ([MR(4)] BCR-ABL1 ≤0.01% on the international scale) at 18 months from the initiation of nilotinib. Of the 1091 patients enrolled, 1089 were considered in the analysis, of whom, 23% (n = 243), 45% (n = 494), 27% (n = 300), and 5% (n = 52) were categorized as young, middle age, elderly, and old, respectively. At 18 months, the rates of MR(4) were 33.9% (95% confidence interval [CI], 27.8-40.0%) in the young, 39.6% (95% CI, 35.3-44.0%) in the middle-aged, 40.5% (95% CI, 34.8-46.1%) in the elderly, and 35.4% (95% CI, 21.9-48.9%) in the old patients. Although the incidence of adverse events was slightly different, no new specific safety signals were observed across the 4 age groups. This subanalysis of the ENEST1st study showed that age did not have a relevant impact on the deep molecular response rates associated with nilotinib therapy in newly diagnosed patients with CML and eventually on the eligibility of the patients to attempt treatment discontinuation.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 6%
Unknown 17 94%

Demographic breakdown

Readers by professional status Count As %
Unspecified 6 33%
Researcher 4 22%
Student > Ph. D. Student 2 11%
Student > Master 2 11%
Other 1 6%
Other 3 17%
Readers by discipline Count As %
Unspecified 6 33%
Pharmacology, Toxicology and Pharmaceutical Science 3 17%
Medicine and Dentistry 3 17%
Agricultural and Biological Sciences 3 17%
Economics, Econometrics and Finance 1 6%
Other 2 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2017.
All research outputs
#7,456,777
of 9,662,012 outputs
Outputs from Journal of Cancer Research & Clinical Oncology
#511
of 778 outputs
Outputs of similar age
#188,566
of 261,274 outputs
Outputs of similar age from Journal of Cancer Research & Clinical Oncology
#10
of 28 outputs
Altmetric has tracked 9,662,012 research outputs across all sources so far. This one is in the 12th percentile – i.e., 12% of other outputs scored the same or lower than it.
So far Altmetric has tracked 778 research outputs from this source. They receive a mean Attention Score of 2.6. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 261,274 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.